Lipirose 20 Tablet contains Rosuvastatin 20 mg, a potent HMG-CoA reductase inhibitor used to manage hypercholesterolemia and mixed dyslipidemia. By selectively inhibiting the enzyme HMG-CoA reductase, Lipirose 20 effectively reduces the synthesis of cholesterol in the liver, leading to decreased levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, while modestly increasing high-density lipoprotein cholesterol (HDL-C). This lipid-modifying agent is indicated for primary hyperlipidemia, familial hypercholesterolemia, and for the prevention of cardiovascular disease in patients at high risk. Lipirose 20 is typically administered once daily, with or without food, and dosage adjustments are based on therapeutic response and patient tolerance. It is essential to combine therapy with lifestyle modifications such as diet, exercise, and weight control to optimize lipid management. Common adverse effects may include headache, myalgia, abdominal pain, and nausea; however, serious side effects like myopathy and hepatotoxicity are rare but warrant monitoring. Liver function tests and creatine kinase levels should be periodically assessed during treatment. Lipirose 20 should be used cautiously in patients with hepatic impairment or a history of muscle disorders and is contraindicated during pregnancy and lactation.